Several of the substances are slated for review by the Pharmacy Compounding Advisory Committee (PCAC), with meetings scheduled as early as July 2026
Citations Citations to this article as recorded by GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications Areesha Moiz, Tetiana Zolotarova, Kristian B Filion, Mark J Eisenberg American Journal of Hypertension.2026
It lowers fasting glucose concentrations and postprandial glucose levels, reduces food intake, and reduces body weight in type 2 diabetics
En pratique, c'est plus nuanc, parce que ton corps rgule en partie cette concentration musculaire et que la simple ingestion d'un supplment ne se traduit pas automatiquement par un stockage musculaire suprieur
This is likely due to how GLP-1 activation affects neurotransmitters and the central nervous system rather than a direct insomnia-causing property of the drug
That timeline is not arbitrary